{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T16:41:36Z","timestamp":1761064896815,"version":"build-2065373602"},"reference-count":0,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"vor","delay-in-days":250,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:p><jats:bold>Study Objective.<\/jats:bold> To determine whether use of nonselective nonsteroidal antiinflammatory drugs (NSAIDs) or cyclooxygenase\u20102 (COX\u20102)\u2010selective inhibitors in patients with coronary stents increased the 3\u2013year rate of major adverse cardiovascular events (MACE).<\/jats:p><jats:p><jats:bold>Design.<\/jats:bold> Population\u2010based cohort study.<\/jats:p><jats:p><jats:bold>Data Sources.<\/jats:bold> The Danish National Patient Registry, the Western Denmark Heart Registry, the Danish Nationwide Prescription Database, the Danish Civil Registration System, and the National Registry of Causes of Deaths.<\/jats:p><jats:p><jats:bold>Patients.<\/jats:bold> A total of 13,001 patients who underwent first\u2010ever percutaneous coronary intervention with stent implantation between January 1, 2002, and June 30, 2005.<\/jats:p><jats:p><jats:bold>Measurements and Main Results.<\/jats:bold> All patients were followed for 3 years after stent implantation for MACE, defined as the first occurrence of myocardial infarction, stent thrombosis, target\u2010lesion revascularization, or cardiac death. Patients' comorbidities were identified from the hospital registries; time\u2010varying use of NSAIDs and concomitant drugs was determined from the Danish Nationwide Prescription Database. For each clinical outcome (MACE), the 3\u2013year risk was computed. We used Cox proportional\u2010hazards regression analysis to compute hazard ratios (HRs) as a measure of relative risk, controlling for potential confounders. During the follow\u2010up period, 5407 patients (41.6%) redeemed at least one NSAID prescription. There were 686 hospitalizations for myocardial infarction (5.3% of patients), 146 for stent thrombosis (1.1%), and 1091 for target\u2010lesion revascularization (8.4%). A total of 1220 patients (9.4%) died during the follow\u2010up period; 637 (4.9%) died of cardiac causes. Compared with no NSAID use, the adjusted HR for MACE was 1.04 (95% confidence interval [CI] 0.83\u20131.31) for nonselective NSAID use and 1.00 (95% CI 0.81\u20131.25) for COX\u20102 inhibitor use.<\/jats:p><jats:p><jats:bold>Conclusion.<\/jats:bold> Use of nonselective NSAIDs or COX\u20102 inhibitors was not associated with an increased rate of MACE in patients with coronary stents. However, we cannot rule out small risks associated with individual NSAIDs.<\/jats:p>","DOI":"10.1592\/phco.31.5.458","type":"journal-article","created":{"date-parts":[[2011,4,25]],"date-time":"2011-04-25T13:56:27Z","timestamp":1303739787000},"page":"458-468","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nonsteroidal Antiinflammatory Drug Use and Cardiovascular Risks After Coronary Stent Implantation"],"prefix":"10.1002","volume":"31","author":[{"given":"Morten","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Maeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens F.","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy L.","family":"Lash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torsten T.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik T.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,6]]},"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.31.5.458","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.31.5.458","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:59:53Z","timestamp":1761062393000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.31.5.458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.1592\/phco.31.5.458"],"URL":"https:\/\/doi.org\/10.1592\/phco.31.5.458","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2011,5]]},"assertion":[{"value":"2012-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}